TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from scPharmaceuticals ( (SCPH) ).
On October 7, 2025, scPharmaceuticals completed a merger where the company was acquired and became a wholly owned subsidiary of the Parent company. This transaction involved the cancellation and conversion of shares, options, and restricted stock units into cash and contingent value rights, with all conditions of the merger agreement satisfied. Following the merger, the company requested the delisting of its shares from Nasdaq and plans to terminate its registration and reporting obligations under the Securities Exchange Act.
The most recent analyst rating on (SCPH) stock is a Hold with a $5.35 price target. To see the full list of analyst forecasts on scPharmaceuticals stock, see the SCPH Stock Forecast page.
Spark’s Take on SCPH Stock
According to Spark, TipRanks’ AI Analyst, SCPH is a Neutral.
scPharmaceuticals’ overall stock score is primarily impacted by its financial instability, with high debt levels and negative cash flows posing significant risks. However, strong technical indicators and positive strategic developments, such as the merger with MannKind Corporation, provide a counterbalance, suggesting potential for future growth. The earnings call further supports optimism with robust revenue growth and strategic advancements, despite ongoing cost challenges.
To see Spark’s full report on SCPH stock, click here.
More about scPharmaceuticals
Average Trading Volume: 1,448,787
Technical Sentiment Signal: Buy
Current Market Cap: $304.4M
Find detailed analytics on SCPH stock on TipRanks’ Stock Analysis page.